Human RCTPubMed ID: 38206348·2024

Retatrutide and Pancreatic Safety: Long-term Biomarker Assessment

Loomba R, Lawitz E, Mantry PS, et al.

Gastroenterology, 2024 · n = 1094

Key finding

No increase in pancreatitis risk (0.2% retatrutide vs 0.1% placebo); amylase/lipase elevations were mild and transient, resolving despite continued treatment.

Summary

Comprehensive safety analysis of retatrutide trials examining amylase, lipase, calcitonin, pancreatic imaging, and pancreatitis incidence across 72-week treatment duration.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT